Akcea and Ionis Announce Positive Phase 2 Clinical Trial Results

Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (IONS), announced positive topline clinical trial results on September 24. The Phase 2 clinical trial is studying the effect of AKCEA-APO(a)-LRx on patients with established cardiovascular disease and elevated levels of lipoprotein(a), known as Lp(a). The goal of the Phase 2 clinical study was to […]

Read more...

Progenics Pharmaceuticals Reports Top Line Phase 3 Clinical Trial Results

On September 13, Progenics Pharmaceutical, Inc. (PGNX) reported Phase 3 clinical trial results from its study of 1404, the company’s prostate specific membrane antigen (PSMA). It is a targeted small molecule SPECT/CT imaging agent designed to visualize prostate cancer. The results met one of the co-primary endpoints of identifying patients without clinically significant prostate cancer. […]

Read more...

ProQR Therapeutics Reports Positive Clinical Trial Results Treating LCA10

On September 5, ProQR Therapeutics, N.V. (PRQR) announced positive results from its Phase 1/2 trial of QR-110 in patients with Leber’s congenital amaurosis 10 (LCA 10) due to a mutation in the CEP290 gene. LCA10 usually leads to childhood blindness and currently has no available treatment options. Patients in the trial had rapid and sustained […]

Read more...

August 2018 Scorecard

The August 2018 scorecard for the signals generated from Sonal can be downloaded here. For more information regarding how you can trade these signals, see the article The Three Moves for Event Based Trading Try Sonal 30 days for free and cancel anytime! Subscribe here and check out the Quickstart Guide FacebookGoogle+Twitter

Read more...